|Aim Immunotech Inc., of Ocala, Fla.||Ampligen (rintatolimod)||Ribonuclease stimulator; 2,5-oligoadenylate synthetase stimulator; TLR-3 agonist; polymerase co-factor VP35 inhibitor||Pancreatic cancer||Candidate from subsidiary NV Hemispherx Biopharma Europe granted orphan medicinal product designation by EC|
|Antengene Corp. Ltd., of Shanghai||Xpovio (selinexor, ATG-010)||Selective inhibitor of nuclear export||Relapsed/refractory multiple myeloma||China's NMPA granted priority review to NDA|
|Kura Oncology Inc., of San Diego||Tipifarnib||Inhibitor of farnesyl transferase||Head and neck squamous cell carcinoma||FDA granted breakthrough therapy designation to treat recurrent or metastatic HRAS mutant disease with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy|
|Pfizer Inc., of New York||TicoVac||Inactivated whole virus vaccine||Tick-borne encephalitis||FDA accepted BLA and granted priority review, setting PDUFA date in August 2021|
|Russian Direct Investment Fund (RDIF), of Moscow||Sputnik V||COVID19 spike glycoprotein modulator||COVID-19 infection||Egyptian Drug Authority granted emergency use authorization|
|Teleflex Inc., of Wayne, Pa.||Freeze-dried plasma||Lyophilized human plasma||Bleeding||BLA submitted to FDA|
For more information about individual companies and/or products, see Cortellis.